Novo Nordisk will invest over 42 billion Danish kroner ($6.01 billion) to boost manufacturing capacity in Kalundborg, Denmark.
Most of the new capacity will be dedicated to manufacturing active pharmaceutical ingredients, including for its blockbuster GLP-1 products for treating diabetes and obesity, which will increase the company’s ability to meet future market demands.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8